Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation | Zendy

Bhausaheb Bagal | Zendy; Arun Chandrasekharan | Zendy; Aliya Chougle | Zendy; Navin Khattry | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation

Author(s) -

Bhausaheb Bagal,

Arun Chandrasekharan,

Aliya Chougle,

Navin Khattry

Publication year - 2017

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2017.02.005

Subject(s) - defibrotide , hepatic veno occlusive disease , medicine , transplantation , stem cell , hematopoietic stem cell transplantation , cardiology , biology , genetics

Hepatic veno-occlusive disease (VOD) is well recognized potentially serious regimen-related toxicity seen after stem cell transplantation. Severe VOD is associated with poor long-term outcomes with very high mortality. Besides supportive care, only defibrotide has been found to be effective in the management of VOD. The recommended dose of defibrotide is 25mg/kg/d but there has been no classical dose finding study done for this drug. A higher dose of defibrotide is associated with increased risk of bleeding and this drug is prohibitively expensive. We report our experience of using fixed low dose of defibrotide in patients with VOD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research